{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:51:30Z","timestamp":1774439490412,"version":"3.50.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Aims:<\/jats:bold> To review the effects of bisphosphonates on bone density, fractures, and bone markers in osteopenic older women.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Relevant articles published before February 2022 were searched in PubMed, EMBASE, and the Cochrane Library. All randomized controlled trials that reported incident fractures, bone mineral density (BMD), bone markers, or adverse events with bisphosphonates in osteopenic older women were included. The quality of included studies was assessed using the Cochrane Risk of Bias tool. The risk ratios (RRs) for fractures, net percent change in bone mineral density and differences in bone markers were calculated using a meta-analysis.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 11 studies were included in our meta-analysis. Bisphosphonates significantly increased the percent changes in the lumbar spine BMD (WMD, 5.60; 95% CI, 4.16\u20137.03; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> = 93.6%), hip BMD (WMD, 4.80; 95% CI, 2.93 to 6.66; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> = 97.1%), total body BMD (WMD, 3.24; 95% CI, 2.12\u20134.35; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> = 90.9%), femoral neck BMD (WMD, 4.02; 95% CI, 1.70\u20136.35; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> = 91.8%) and trochanter BMD (WMD, 5.22; 95% CI, 3.51\u20136.93; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> = 83.6%) when compared to placebo. Zoledronate was associated with a great treatment effect on fragility fracture (RR, 0.63; 95% CI, 0.50\u20130.79), clinical vertebral fracture (RR, 0.41; 95% CI, 0.22\u20130.76), and radiographic vertebral fracture (RR, 0.60; 95% CI, 0.27\u20131.35) compared to placebo. Meanwhile, alendronate was also associated with beneficial effects on fragility fracture (RR, 0.40; 95% CI, 0.15\u20131.07), clinical vertebral fracture (RR, 0.46; 95% CI, 0.17\u20131.24), and radiographic vertebral fracture (RR, 0.64; 95% CI, 0.38\u20131.09). In addition, the use of bisphosphonates reduced the concentration of procollagen type I N-terminal propeptide (PINP) and C-terminal telopeptide of type I collagen (CTX) over placebo by 15.79 (95% CI, \u221218.92 to \u221212.66; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> = 28.4%), \u22120.23 (95% CI, \u22120.35 to \u22120.10; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> = 91.3%), respectively. Although there was insufficient evidence to determine their safety, these bisphosphonates may have an effect on cancer, cardiac events, and mortality in osteopenic older women.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> All bisphosphonates examined were associated with beneficial effects on fractures, BMD, and bone markers in women with osteopenia. Further randomized controlled trials are necessary to clarify the safety of bisphosphonates in women with osteopenia.<\/jats:p>","DOI":"10.3389\/fphar.2022.892091","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T05:26:10Z","timestamp":1652937970000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Effects of Bisphosphonates Treatments in Osteopenic Older Women: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Jiangbi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songqi","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiecheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/jbmr.2847","article-title":"Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women with Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data","volume":"31","author":"Bell","year":"2016","journal-title":"J. Bone Miner Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","article-title":"Treatment-related Changes in Bone mineral Density as a Surrogate Biomarker for Fracture Risk Reduction: Meta-Regression Analyses of Individual Patient Data from Multiple Randomised Controlled Trials","volume":"8","author":"Black","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1210\/jc.2009-0852","article-title":"Effect of Osteoporosis Treatment on Mortality: a Meta-Analysis","volume":"95","author":"Bolland","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1359\/jbmr.090704","article-title":"Potential Mediators of the Mortality Reduction with Zoledronic Acid after Hip Fracture","volume":"25","author":"Col\u00f3n-Emeric","year":"2010","journal-title":"J. Bone Miner Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.bone.2011.07.020","article-title":"Bone-bound Bisphosphonate Inhibits Growth of Adjacent Non-bone Cells","volume":"49","author":"Cornish","year":"2011","journal-title":"Bone"},{"key":"B7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1210\/er.2001-3002","article-title":"Meta-analyses of Therapies for Postmenopausal Osteoporosis. III. Meta-Analysis of Risedronate for the Treatment of Postmenopausal Osteoporosis","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr. Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1210\/er.2001-2002","article-title":"Meta-analyses of Therapies for Postmenopausal Osteoporosis. II. Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","article-title":"Epidemiology and Outcomes of Osteoporotic Fractures","volume":"359","author":"Cummings","year":"2002","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00198-017-3906-6","article-title":"International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the Screening of Adherence to Oral Bisphosphonates","volume":"28","author":"Diez-Perez","year":"2017","journal-title":"Osteoporos. Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant Bisphosphonate Treatment in Early Breast Cancer: Meta-Analyses of Individual Patient Data from Randomised Trials","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S2213-8587(17)30184-5","article-title":"Use of Bone Turnover Markers in Postmenopausal Osteoporosis","volume":"5","author":"Eastell","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11154-011-9187-z","article-title":"Treatment of Osteopenia","volume":"13","author":"Eriksen","year":"2012","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"B14","doi-asserted-by":"publisher","first-page":"E1130","DOI":"10.1503\/cmaj.161207","article-title":"Duration of Antiresorptive Activity of Zoledronate in Postmenopausal Women with Osteopenia: a Randomized, Controlled Multidose Trial","volume":"189","author":"Grey","year":"2017","journal-title":"CMAJ"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.bone.2012.03.016","article-title":"Five Years of Anti-resorptive Activity after a Single Dose of Zoledronate-Rresults from a Randomized Double-Blind Placebo-Controlled Trial","volume":"50","author":"Grey","year":"2012","journal-title":"Bone"},{"key":"B16","volume-title":"Cochrane Handbook for Systemic Reviews of Interventions","author":"Higgins","year":"2021"},{"key":"B17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/bcr2769","article-title":"Anti-tumour Activity of Bisphosphonates in Preclinical Models of Breast Cancer","volume":"12","author":"Holen","year":"2010","journal-title":"Breast Cancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1097\/MD.0000000000001007","article-title":"Dose-Effectiveness Relationships Determining the Efficacy of Ibandronate for Management of Osteoporosis: A Meta-Analysis","volume":"94","author":"Hou","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The Diagnosis of Osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"J. Bone Miner Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2016.06.039","article-title":"Bisphosphonates for Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis","volume":"252","author":"Kranenburg","year":"2016","journal-title":"Atherosclerosis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00198-013-2575-3","article-title":"Risk of Osteonecrosis in Patients Taking Bisphosphonates for Prevention of Osteoporosis: a Systematic Review and Meta-Analysis","volume":"25","author":"Lee","year":"2014","journal-title":"Osteoporos. Int."},{"key":"B22","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies that Evaluate Healthcare Interventions: Explanation and Elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1097\/AOG.0b013e3181bdce0a","article-title":"Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women with Low Bone Mass: a Randomized Controlled Trial","volume":"114","author":"McClung","year":"2009","journal-title":"Obstet. Gynecol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.bone.2008.09.011","article-title":"Efficacy and Safety of Monthly Oral Ibandronate in the Prevention of Postmenopausal Bone Loss","volume":"44","author":"McClung","year":"2009","journal-title":"Bone"},{"key":"B26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1359\/JBMR.0301202","article-title":"Oral Daily Ibandronate Prevents Bone Loss in Early Postmenopausal Women without Osteoporosis","volume":"19","author":"McClung","year":"2004","journal-title":"J. Bone Miner Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00198-015-3145-7","article-title":"Response of Bone Turnover Markers to Three Oral Bisphosphonate Therapies in Postmenopausal Osteoporosis: the TRIO Study","volume":"27","author":"Naylor","year":"2016","journal-title":"Osteoporos. Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1007\/s00198-006-0135-9","article-title":"The Population burden of Fractures Originates in Women with Osteopenia, Not Osteoporosis","volume":"17","author":"Pasco","year":"2006","journal-title":"Osteoporos. Int."},{"key":"B29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.4065\/80.3.343","article-title":"Effect of Alendronate on Vertebral Fracture Risk in Women with Bone mineral Density T Scores of-1.6 to -2.5 at the Femoral Neck: the Fracture Intervention Trial","volume":"80","author":"Quandt","year":"2005","journal-title":"Mayo Clin. Proc."},{"key":"B30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/jbmr.3860","article-title":"Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women","volume":"35","author":"Reid","year":"2020","journal-title":"J. Bone Miner Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture Prevention with Zoledronate in Older Women with Osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of Action of Bisphosphonates: Similarities and Differences and Their Potential Influence on Clinical Efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos. Int."},{"key":"B33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.bone.2016.05.013","article-title":"Clinical Effectiveness of Bisphosphonates for the Prevention of Fragility Fractures: A Systematic Review and Network Meta-Analysis","volume":"89","author":"Sanderson","year":"2016","journal-title":"Bone"},{"key":"B34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.bone.2019.04.016","article-title":"Comparison of Risedronate versus Placebo in Preventing Anastrozole-Induced Bone Loss in Women at High Risk of Developing Breast Cancer with Osteopenia","volume":"124","author":"Sestak","year":"2019","journal-title":"Bone"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","article-title":"Bone mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures","volume":"164","author":"Siris","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/j.clinthera.2007.09.017","article-title":"Effects of Risedronate 5 Mg\/d on Bone mineral Density and Bone Turnover Markers in Late-Postmenopausal Women with Osteopenia: a Multinational, 24-month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Trial","volume":"29","author":"V\u00e4lim\u00e4ki","year":"2007","journal-title":"Clin. Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e544","DOI":"10.1097\/MJT.0000000000000415","article-title":"Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials","volume":"24","author":"Wang","year":"2017","journal-title":"Am. J. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1002\/jbmr.2269","article-title":"The Recent Prevalence of Osteoporosis and Low Bone Mass in the United States Based on Bone mineral Density at the Femoral Neck or Lumbar Spine","volume":"29","author":"Wright","year":"2014","journal-title":"J. Bone Miner Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.26355\/eurrev_201903_17414","article-title":"Drug Efficacies on Bone mineral Density and Fracture Rate for the Treatment of Postmenopausal Osteoporosis: a Network Meta-Analysis","volume":"23","author":"Yang","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/s8756-3282(00)00384-7","article-title":"Effects of Alendronate on Osteopenic Postmenopausal Chinese Women","volume":"27","author":"Yen","year":"2000","journal-title":"Bone"},{"key":"B41","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/os.12701","article-title":"Fall Prevention and Anti-osteoporosis in Osteopenia Patients of 80 Years of Age and Older: A Randomized Controlled Study","volume":"12","author":"Zhou","year":"2020","journal-title":"Orthop. Surg."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.892091\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T05:26:19Z","timestamp":1652937979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.892091\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":41,"alternative-id":["10.3389\/fphar.2022.892091"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.892091","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"article-number":"892091"}}